Epicardial Fat
Conditions
Brief summary
Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown
Detailed description
This is a retrospective, observational, case control study. Data were obtained from retrospective review of the electronic medical records. Patients were treated with either semaglutide, dulaglutide or metformin as standard of care, during routine clinical practice, regardless of the study. Each patient underwent routine labs and an onsite ultrasound measurement of EAT thickness at baseline and at the routine 12-week follow up visit, as standard of care.
Interventions
None listed
Sponsors
University of Miami
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes, * BMI ≥27 kg/m2, * Age ≥ 18 years old
Exclusion criteria
* Type 1 diabetes * Concurrent use of dipeptidyl peptidase 4 (DPP-4) inhibitors or other GLP-1 agonist receptors * History of diabetic ketoacidosis * Known contraindications to GLP-1 receptor agonists such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2 * Acute infective diseases, cancer or chemotherapy * Use of systemic corticosteroids within the 3 months prior this study * Known or suspected allergy to semaglutide or dulaglutide excipients or related products * Pregnancy, breastfeeding or the intention of becoming pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Epicardial Fat thickness | 12 weeks | Ultrasound measured Epicardial Fat thickness |
Countries
United States
Outcome results
None listed